Business Context and Reporting Period
This Form 8-K is filed by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc., which is the target of a proposed business combination) on December 18, 2024. The filing reports the entry into a material definitive agreement to secure financing necessary to consummate a previously announced merger with Aspire Biopharma, Inc.
Key Financial Metrics
The filing details a specific financing transaction rather than standard operating financials. Key metrics include:
- Debt Facility: A promissory note allowing for loans up to $500,000.
- Principal Drawn: $184,543.80 as of the filing date.
- Interest Rate: 10% per annum.
- Original Issue Discount (OID): 20%.
- Exit Fee: 10% of the principal amount and accrued interest upon maturity.
- Maturity Date: The earlier of June 1, 2025, or the date the Company raises at least $5,000,000 in gross proceeds from a debt or equity offering.
- Liquidity: The filing does not provide a total cash balance or liquidity position for the Company.
Material Changes
The primary material change is the execution of the "Blackstone Transaction" with Blackstone Capital Advisors, Inc. on December 18, 2024 (effective December 13, 2024). This transaction includes:
- A subscription agreement and promissory note to fund the business combination.
- A registration rights agreement for "Commitment Shares."
- Upon closing of the merger, the Sponsor will transfer three Class A ordinary shares of PowerUp to Blackstone for every dollar loaned.
Guidance, Outlook, and Risks
Outlook: The financing is intended to facilitate the closing of the Business Combination with Aspire Biopharma. The Company anticipates the need to raise at least $5,000,000 in additional capital to trigger the maturity of the current note.
Risks and Contingencies: The filing contains extensive forward-looking statements regarding the merger. Key risks include:
- Failure to complete the business combination by the deadline.
- Shareholder redemptions exceeding anticipated levels.
- Failure to meet Nasdaq listing standards post-combination.
- Aspire's inability to execute growth strategies, secure intellectual property, or commercialize products.
- Regulatory or legal proceedings that could terminate the agreement.
Investor Verification Checklist
- Verify the total cash on hand and burn rate of PowerUp Acquisition Corp. to assess runway before the June 1, 2025, maturity date.
- Confirm the status of the $5,000,000 capital raise required to extend the note's maturity.
- Review the definitive proxy statement (Form S-4) for details on shareholder redemption levels and the final terms of the merger.
- Assess the dilution impact of the "Commitment Shares" to be issued to Blackstone upon closing.
- Monitor Aspire Biopharma's clinical or commercial progress, as the merger's success depends on its future performance.